Yi Yang, Xu Yanan, Jiang Haibing, Wang Jun
Department of Cardiology Fourth Ward, Xinjiang Medical University Affiliated Hospital of Traditional Chinese Medicine, Urumqi, China.
Department of Respiratory Medicine, The People's Hospital of Xuancheng City, Xuancheng, China.
Front Cardiovasc Med. 2021 Mar 15;8:629958. doi: 10.3389/fcvm.2021.629958. eCollection 2021.
Recent evidence indicates that a large proportion of deaths from coronavirus disease 2019 (COVID-19) can be attributed to cardiovascular disease, including acute myocardial infarction, arrhythmias and heart failure. Indeed, severe infection increases the risk of heart failure among patients with COVID-19. In most patients, heart failure arises from complex interactions between pre-existing conditions, cardiac injury, renin-angiotensin system activation, and the effects of systemic inflammation on the cardiovascular system. In this review, we summarize current knowledge regarding pathogen-driven heart failure occurring during treatment for COVID-19, the potential effects of commonly used cardiovascular and anti-infective drugs in these patients, and possible directions for establishing a theoretical basis for clinical treatment.
近期证据表明，2019冠状病毒病（COVID-19）导致的很大一部分死亡可归因于心血管疾病，包括急性心肌梗死、心律失常和心力衰竭。事实上，严重感染会增加COVID-19患者发生心力衰竭的风险。在大多数患者中，心力衰竭源于既往疾病、心脏损伤、肾素-血管紧张素系统激活以及全身炎症对心血管系统的影响之间的复杂相互作用。在本综述中，我们总结了关于COVID-19治疗期间病原体驱动的心力衰竭的现有知识、这些患者常用心血管和抗感染药物的潜在影响，以及为临床治疗建立理论基础的可能方向。
